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Abstract
Objective: The FTO A/T polymorphism (rs9939609) is a strong candidate to influence obesity-related traits. Elite athletes
from many different sporting disciplines are characterized by low body fat. Therefore, the aim of this study was to assess
whether athletic status is associated with the FTO A/T polymorphism.
Subjects and Methods: A large cohort of European Caucasians from Poland, Russia and Spain were tested to examine the
association between FTO A/T polymorphism (rs9939609) and athletic status. A total of 551 athletes were divided by type of
sport (endurance athletes, n = 266 vs. sprint/power athletes, n = 285) as well as by level of competition (elite-level vs.
national-level). The control group consisted of 1,416 ethnically-matched, non-athletic participants, all Europeans.
Multinomial logistic regression analyses were conducted to assess the association between FTO A/T genotypes and
athletic status/competition level.
Results: There were no significantly greater/lesser odds of harbouring any type of genotype when comparing across athletic
status (endurance athletes, sprint/power athletes or control participants). These effects were observed after controlling for
sex and nationality. Furthermore, no significantly greater/lesser odds ratios were observed for any of the genotypes in
respect to the level of competition (elite-level vs. national-level).
Conclusion: The FTO A/T polymorphism is not associated with elite athletic status in the largest group of elite athletes
studied to date. Large collaborations and data sharing between researchers, as presented here, are strongly recommended
to enhance the research in the field of exercise genomics.
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Introduction
There is emerging evidence that elite athletes or former elite
athletes are predisposed towards longer life expectancy, and lower
risk of chronic diseases such as obesity and type 2 diabetes, than
matched sedentary controls [1–3]. A twenty-year follow-up on
former elite athletes revealed that several risk factors (smoking,
diabetes, obesity) were never present among the athletes, and the
prevalence of other risk factors remained low after twenty years
[3].
Genetic factors may contribute to the low predisposition of elite
athletes to the aforementioned disease conditions. Specifically, the
A/T polymorphism (rs9939609) in the fat mass and obesity
associated (FTO) gene (which codes for the protein alpha-
ketoglutarate-dependent dioxygenase FTO, also known as fat
mass and obesity-associated protein) is a strong candidate to
explain how disease modifier polymorphisms may contribute to
lower risk for obesity among trained individuals [4]. The FTO A/
T polymorphism has initially been identified as a risk factor for
obesity by two independent genome-wide association studies
(GWAS) [5,6]. It has been shown that adults who are homozygous
for the A-allele weigh on average 1.5 to 3 kg more than those
homozygous for the T allele. This finding has now been replicated
in multiples obese cohorts [7].
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Exercise may attenuate the association between FTO A/T
polymorphism and obesity related-traits. The association between
FTO A/T polymorphism and body mass index (BMI) is
significantly weaker in individuals with higher exercise levels [8].
This phenomenon has been confirmed in Caucasian and African-
American cohorts [9,10]. A recent meta-analysis data, that was
calculated from 45 studies of adults (n = 218,166) and 9 studies of
children and adolescents (n = 19,268) has shown that the A-allele
increased the risk of obesity 30% less in the physically active group
than in their inactive peers [4]. Keeping in mind that elite athletes
represent the end point of the human physical activity levels, the
FTO A/T polymorphism might be a novel target to influence elite
athletic status.
Therefore, the aim of the present study was to compare the
frequency distribution of the FTO A/T polymorphism (rs9939609)
between elite endurance athletes, elite sprint/power athletes, and
ethnically-matched, non-athletic control participants in a large
group of Europeans (including Spanish, Polish and Russian
cohorts). We also examined the association of the FTO A/T
polymorphism with respect to the level of achievement of the
athletes (‘elite-level’ and ‘national-level’), in both endurance and
sprint/power athletes. We hypothesized that the frequency of the
A-allele or the AA genotype will be lower among elite athletes
compared with control participants.
Materials and Methods
The study was conducted according to the Declaration of
Helsinki. Written informed consent was obtained from all
participants, and the study was approved by the ethics committees
of Universidad Europea de Madrid, Spain, the Pomeranian Medical
University, Poland, and the Kazan State Medical University, Russia.
Participants
A total of 551 athletes (266 endurance athletes and 285 power
athletes) and 1416 control participants, from Poland, Russia and
Spain, volunteered to participate in this study. All participants
were unrelated European men (76%) or women (23%), and all of
European descent (as self-reported) for $3 generations. The
sample included elite athletes (57%) who had competed at an
international level (European or World championships, or
Olympic Games) and national-level athletes (43%) who partici-
pated in their chosen sport at a national level only. The
competition level differentiation was made according to the
athletes’ best individual performances. The athletes were only
included if they had never tested positive in anti-doping controls.
Control participants were required to be free of any diagnosed
cardiorespiratory disease and not participating regularly in any
competitive or structured sport or physical activity (i.e. performing
less than 3 sessions per week of strenuous exercise such as running,
swimming, bicycling or weight lifting).
Spanish cohort. The Spanish cohort (n = 192) were all male
and included 81 elite athletes (mean 6 SD mass = 62.066.3 kg)
and 60 control participants (71.968.3 kg):
(i) 32 elite sprint/power athletes (mean age = 2663 yr).
Thirteen track and field athletes were Olympians during
the period 2000–2008.
(ii) 49 elite endurance athletes (2764 yr). This sample included
49 elite endurance runners (the top Spanish runners during
the 1999–2009 periods, i.e. mainly 5000 m to marathon
specialists, virtually all of them Olympians).
(iii) 60 healthy, non-athletic control participants (2062 yr). All
were undergraduate students from the same university
(Universidad Europea de Madrid, Spain).
Polish cohort. The Polish cohort (n = 844), were all male and
included 214 athletes (mean 6 SD mass = 71.366.2 kg) and 630
control participants (79.266.1 kg). Of the athletes, 132 were
classified as elite and 82 were national-level athletes:
(i) 101 power athletes (2868 yr). This group included weigh-
tlifters (n = 42), sprinters (#400 m, n= 33), and track and
field jumpers (n = 26). This group included 63 (62%) elite
athletes.
(ii) 113 endurance athletes (2666 yr). This group included
rowers (n = 53), endurance road cyclists (n = 14), 5,000 m
runners (n = 12), marathon runners (n = 12), 800–1,500 m
swimmers (n = 11), 15–50 km cross-country skiers (n = 7),
and triathletes (n = 4). This group included 69 (61%) elite
athletes.
(iii) 630 healthy, non-athletic control participants (2162 yr). All
the control participants were students of the University of
Szczecin.
Russian cohort. The Russian cohort (men and women,
n = 982) included 256 athletes (187 men, 69 women;
70.3616.8 kg) and 726 control participants (328 men and 398
women; 61.2612.2 kg). Of the athletes 105 were classified as elite
and 151 were classified as national-level athletes:
(i) 152 power athletes (2468 yr). This group included: 100–
200 m sprinters (n = 18), track and field jumpers (n = 47),
short distance speed skaters (500–1000 m; n= 9), 50–100 m
swimmers (n = 13), and weight lifters (n = 65). The group
included 71 (47%) elite athletes.
(ii) 104 endurance athletes (2062 yr). This group included
rowers (n = 36), long distance runners (5000 m; n= 27), road
cyclists (n = 12), long distance speed skaters (5–10 km; n= 7),
skiers (n = 15) and long distance swimmers (800–1500 m;
n= 7).The group included 34 (33%) elite athletes.
(iii) 726 healthy, non-athletic control participants (2165 yr). All
the control participants were citizens of Moscow and Kazan.
Genotyping
We followed recent recommendations for genotype-phenotype
association studies provided by Chanock et al. [11], Attia et al.
[12] and the latest ‘Strengthening the Reporting of Genetic
Association studies’ (STREGA) group report [13].
Spanish cohort. Genomic DNA was isolated from buccal
epithelium or peripheral blood during the years 2004–2008 and
genotyping was performed during 2012 in the Genetics Labora-
tory of Ariel University Centre, Israel. Polymerase chain reaction
(PCR) was performed in order to amplify the sequence containing
the mutation. A fragment of 105 bp was amplified with the
following primers: FTO- F 59- GGT TCC TTGCGA CTG CTG
TGA AAT T ’3 and FTO-R 5’ GCT TTT ATGCTC TCC CAC
TC ’3. The PCR conditions were as follows: initial denaturing at
95uC 5 min; 35 cycles at 95uC 30 s, 60uC 30 s, 72uC 30 s and a
final extension at 72uC 10 min. FTO genotypes were established
by enzymatic digestion of amplicons with ApoI and by allelic
discrimination assay on a Real-Time Polymerase Chain Reaction
(PCR) instrument (Stratagene Mx3000D) with TaqmanH probes
(Genotyping ToughMixH). Following recent recommendations
[11], we replicated the genotype results of the Spanish cohort (in
FTO Polymorphism and Elite Athletic Performance
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40% of samples) using a different method, i.e. direct sequencing.
The results from the two different methods were in 100%
agreement.
Polish cohort. Genomic DNA was isolated from buccal
epithelium using GenElute Mammalian Genomic DNA Miniprep
Kit (Sigma, Germany) during the years 2008–2010, according to
the producer protocol. All samples were genotyped during 2012,
in the Pomeranian Medical University using an allelic discrimination
assay on a Rotor-Gene Real-Time Polymerase Chain Reaction
(PCR) instrument (Corbett, Australia) with TaqmanH probes. For
the discrimination of FTO A and T alleles (rs9939609), a
TaqManH Pre-Designed SNP Genotyping Assay was used
(Applied Biosystems, USA) (assay ID: C__30090620_10), includ-
ing primers and fluorescently labelled (FAM and VIC) MGBTM
probes for the detection of both alleles.
Russian cohort. Genomic DNA was isolated from epithelial
mouth cells using a DNK-sorb-A sorbent kit according to the
manufacturer’s instruction (Central Research Institute of Epide-
miology, Moscow, Russia). Genotyping for the FTO gene
polymorphism was performed during 2012, at the Laboratory of
Molecular Genetics, Kazan State Medical University by PCR on a
multicanal amplificator Tercyk (DNA Technology, Moscow,
Russia) and restriction enzyme digestion [14].
Following recent recommendations [11], we replicated the
genotype results of a subset of samples (i.e. 40% of samples of the
Russian cohort) using a different method, i.e. by MALDI-TOF
mass spectrometry [15].
Statistical analysis
Chi squared tests were used to test for the presence of Hardy-
Weinberg equilibrium (HWE). Genotype and allele frequencies
were compared according to athletic status (i.e. control partici-
pants, endurance, or sprint/power athlete) using Fisher’s exact
test. Multinomial logistic regression analyses were conducted to
assess the association between genotype and athletic status/
competition level. In each case, gender and nationality were
controlled for; and analyses were made comparing AA (reference
group) vs. AT; AA vs. TT (co-dominant effect); AA vs. TT and TA
combined (dominant effect); AA and TA combined (reference
group) vs. TT (recessive effect). Significance was accepted when
p#0.05.
Results
Replication analysis with a different genotyping method yielded
100% agreement. There were no significant differences in age
between cohorts. This added to the homogeneity of the study
population and allowed us to pool the three cohorts to examine the
association between physical performance level and FTO A/T
polymorphism.
Table 1 shows the genotype and allele frequency distributions
amongst all participants according to their nationality. Genotype
distributions of all control and athletic groups met HWE (all
p.0.1). In the Russian sample, no differences were observed in the
proportion of men and women participating in endurance and
power sports (p.0.05) and genotype and allele frequencies were
similar according to gender (p.0.05; data not shown). For these
reasons, gender was considered as a covariate only in further
analyses (see below).
Table 2 shows the association between genotype and athletic
status for all participants. There were no significantly greater/
lesser odds of harbouring any type of genotype when comparing
Table 1. FTO A/T polymorphism genotype and allele frequencies amongst all participants according to their nationality.
Spanish cohort Polish cohort Russian cohort
Control Endurance Power Control Endurance Power Control Endurance Power
All 60 49 32 630 113 101 726 104 152
AA 5 (8.3) 5 (10.2) 4 (12.5) 119 (18.9) 13 (11.5) 19 (18.8) 111 (15.3) 17 (16.3) 27 (17.8)
AT 7 (11.7) 14 (28.6) 7 (21.8) 318 (50.5) 65 (57.5) 52 (51.5) 324 (44.6) 54 (51.9) 68 (44.7)
TT 48 (80) 30 (61.2) 21 (65.6) 193 (30.6) 35 (31.0) 30 (29.7) 291 (40.1) 33 (31.7) 57 (37.5)
MAF 0.141 0.245 0.234 0.441 0.403 0.446 0.376 0.423 0.401
HWE-P
value
.001 0.282 0.086 0.838 0.115 0.914 .001 0.810 0.696
Abbreviations: HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency.
doi:10.1371/journal.pone.0060570.t001
Table 2. The association between FTO A/T genotypes and athletic status in three cohorts of European participants.
Power vs. Control Endurance vs. Power Endurance vs Control All athletes vs Control
OR CI p OR CI p OR CI p OR CI p
AA (ref) 1 1 1 1
AT 0.95 (0.66–1.36) 0.782 1.48 (0.89–2.45) 0.129 1.46 (0.97–2.18) 0.070 1.15 (0.86–1.54) 0.349
TT 1.01 (0.70–1.46) 0.968 1.16 (0.69–1.96) 0.569 1.30 (0.85–1.98) 0.229 1.11 (0.82–1.50) 0.484
AT-TT (AA ref) 0.98 (0.70–1.37) 0.892 1.33 (0.82–2.14) 0.238 1.39 (0.94–2.05) 0.097 1.14 (0.86–1.49) 0.363
TT (AA-AT ref) 1.05 (0.80–1.36) 0.742 0.87 (0.61–1.24) 0.426 0.98 (0.74–1.29) 0.858 1.00 (0.82–1.24) 0.969
Note. OR: Odds ratio; CI: Confidence intervals; p: 2-tailed p value with significance assumed at p,0.05.
doi:10.1371/journal.pone.0060570.t002
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the power, endurance and control groups. Likewise, no differences
were observed when comparing all athletes to the control group.
These effects were observed after controlling for the effects of
gender and nationality.
Table 3 shows the association between genotype and compe-
tition level (elite vs. national level) for the endurance and power
athletes from all countries. No significantly greater/lesser odds
ratios were observed for any of the genotypes in either competition
level. As above, gender and nationality were controlled for in the
regression analyses.
Figure 1 shows the percentage of genotypes present in elite-level
athletes according to nationality and athletic status. No significant
genotype differences were observed between elite endurance
athletes and elite power athletes across nationalities.
Figure 2 shows the percentage of genotypes present in national-
level athletes according to nationality and athletic status. No
significant genotype differences were observed between national-
level endurance athletes and national-level power athletes across
nationalities.
Discussion
We have analysed, for the first time, the association between
FTO A/T polymorphism (rs9939609) and elite athletic status in a
large cohort of European athletes. No significant differences were
observed in genotype/allele frequencies when comparing between
the three groups (endurance athletes, sprint/power athletes, and
non-athletic controls) or when comparing between the groups with
respect to the level of performance (elite vs. national-level),
suggesting that this polymorphic marker is not related to elite
athletic performance.
In the present study we explored the association between the
FTO A/T polymorphism and athletic performance in elite athletes
from several cohorts. Taken individually, the results from our
three cohorts are probably limited by relatively small sample size
of the individual cohorts, and low statistical power. In an attempt
to overcome the barrier of sample size, and the difficulty of
gathering a homogenous cohort of elite athletes in each sporting
discipline, we have recruited a total of 551 athletes (266 endurance
athletes and 285 power/sprint athletes), all of European descent
for $3 generations. Indeed, it has been estimated that testing a
single variant using a case (athletes):control (non-athletes) design
would require ,250 cases to obtain a statistical power of 80%
[16]. A sufficient sample size of elite athletes, together with
following recent recommendations for association studies, are
probably necessary to reach solid conclusions in the field of genes
and elite performance [17].
Genetic variants such as the FTO A/T polymorphism studied
here are associated with increased BMI and energy intake [9,18],
and are thus candidates to influence obesity and other disease-
related phenotypes. Conversely, such variants may also influence
elite athletic performance because body composition and BMI are
well-characterised phenotypes in athletic populations that, to some
extent at least, differentiate between athletes of different achieve-
ment levels, and between athletes and non-athletes. However,
there are some complex interrelationships between increased/
decreased BMI and both physical activity levels (i.e., energy
expenditure) and energy intake, affected by interconnected
metabolic processes [18,19]. Indeed, physical activity was recently
shown to attenuate the influence of FTO variants on obesity risk
[4].
The duality of specific polymorphisms associated with both
obesity and athletic performance has been well demonstrated. A
good example is the peroxisome proliferator-activated receptor
gamma coactivator1a (PPARGC1A) Gly482Ser polymorphism, in
which the 482Ser allele is associated with increased risk of obesity
Table 3. The association between FTO A/T genotypes and
athletic status according to level of competition (elite
compared to national level), in three cohorts of European
participants.
Endurance Power
OR CI p OR CI p
AA (ref) 1 1
AT 0.79 (0.22–2.87) 0.719 1.61 (0.79–3.27) 0.187
TT 2.08 (0.83–5.23) 0.116 1.93 (0.93–4.03) 0.079
AT-TT (AA ref) 2.14 (0.93–4.96) 0.076 1.75 (0.90–3.39) 0.099
TT (AA-AT ref) 1.13 (0.63–2.05) 0.682 1.37 (0.81–2.33) 0.241
Note. OR: Odds ratio; CI: Confidence intervals; p: 2-tailed p value with
significance assumed at p,0.05.
doi:10.1371/journal.pone.0060570.t003
Figure 1. Genotype distributions in elite-level athletes accord-
ing to nationality and athletic status.
doi:10.1371/journal.pone.0060570.g001
Figure 2. Genotype distributions in national-level athletes
according to nationality and athletic status.
doi:10.1371/journal.pone.0060570.g002
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and type 2 diabetes [20], whereas the ‘favourable’ Gly482 allele is
associated with elite athletic performance [21–24]. Interestingly,
the minor Ser482 allele is associated with risk of obesity in inactive
individuals [20,25] supporting the notion that genetic susceptibility
to obesity is enhanced by physical inactivity. The link between
PPARGC1A gene and fat oxidative metabolism suggest that this
gene may influence athletic performance on one hand, and
prevention of obesity on the other hand. Additional examples of
polymorphisms that were found to be associated with both obesity
and elite athletic performance are the ADRB2 Arg16Gly
(rs1042713) [26,27], and the ADRB3 Trp64Arg (rs4994) [28,29].
The FTO A/T polymorphism (rs9939609) is located in the first
intron of the FTO gene, which is expressed mainly in the brain,
skeletal muscles and adipose tissue [30]. The mechanism by which
it influences adiposity and attenuates physical activity is mostly
unknown and probably multifaceted. Mechanistic research
involving mice models demonstrated alternation in food intake
in mice expressing several copies of the FTO gene, and significant
reduction in adipose tissue and lean body mass [31]. A knockout
mice model revealed that the FTO gene is functionally involved in
energy homeostasis, mitochondrial coupling and substrate cycling
by controlling energy expenditure [32]. The FTO A/T polymor-
phism was shown to affect energy efficiency potentially by
influencing mitochondrial coupling in human type I (oxidative)
muscle fibres [33], and FTO mRNA expression in human skeletal
muscle correlates with whole-body substrate oxidation rates [34].
Thus, it could have been hypothesized that elite endurance
performance in particular, which traditionally requires a high
proportion of type I skeletal muscle fibres in the locomotory
muscles and high mitochondrial coupling, would be influenced by
the FTO A/T polymorphism.
To summarize, (i) the potential involvement of the FTO gene in
energy metabolism and muscle function, (ii) the fact that other
gene polymorphisms have been shown to be associated with both
obesity and athletic performance (e.g. PPARGC1A Gly482Ser,
ADRB3 Trp64Arg, and the ADRB2 Arg16Gly), (iii) the interaction
between the FTO A/T polymorphism and physical activity levels,
(iv) the low percentage of body fat characteristic of elite athletes
excelling in both endurance and many sprint/power events (v) the
lower risk of obesity in former elite athletes, and (vi) the suggestive
role of the FTO gene in muscle performance, encouraged us to
hypothesize that the FTO A/T polymorphism was associated with
elite athletic status. However, no association was found between
the FTO A/T polymorphism and athletic status in the largest
group of elite athletes studied to date. Elite athletic status is a
polygenic trait with several candidate gene variants (most of which
likely remain unidentified) playing a certain role, either alone
(which does not seem to be the case with the FTO A/T variation),
or through complex, gene-gene and gene-environment interac-
tions [35,36]. Large collaborations and data sharing between
researchers, as presented here, are strongly recommended to
enhance the research in the field of exercise genomics.
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